...
首页> 外文期刊>Cureus. >Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
【24h】

Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study

机译:用于1型糖尿病患者的新型推注计算器(IF-DIABETE)的可行性和效率:非沉积的单臂试验研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The IF-DIABETE?system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE?system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE?smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 ± 3 years. Over a six months’ period of the study, the mean HbA1c level decreased from 8.3 ± 0.8% to 7.0 ± 0.5 % with a reduction in mild hypoglycemic events’ frequency from 5 ± 3 to 1 ± 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 ± 0.5 to 5 ± 1 tests per day. Conclusion The IF-DIABETE?system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events.
机译:背景技术IF-yatbete?系统是一种胰岛素推注剂量支持,被认为是第一型推注计算器,致力于患有阿拉伯语的1型糖尿病的人,并适应大型阿拉伯食品文化。我们的目标是评估IF-&型糖尿虱的概念和效率证明吗?系统改善1型糖尿病患者的临床和代谢结果。方法这是一个预期的非粗糙单臂试验研究。我们的患者使用IF-DIABETE?智能手机应用为新型推注计算器。在研究的六个月内,考虑的主要结果是血红蛋白糖化(HBA1C),我们确定了低血糖事件,体重指数(BMI)和血糖测量的频率作为二次结果。结果招收了21名糖尿病患者。平均年龄为21±3年。在研究的六个月内,平均HBA1C水平从8.3±0.8%降至7.0±0.5%,降低低血糖事件的频率从5±3至1±0.7剧集/ 3个月。我们没有观察到BMI的任何变化,血糖测试的频率从每天增加2±0.5至5±1测试。结论IF-yatbete?系统安全有效地支持有1型糖尿病以改善其代谢控制的个体。在六个月后,患者能够改善血糖控制而不增加降血糖事件的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号